@article{b1b0771e379e4289b2d981d57e901747,
title = "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma",
abstract = "Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.",
author = "Meng Li and Hong Zhao and Xiaosong Zhang and Wood, {Laura D.} and Anders, {Robert A.} and Choti, {Michael A.} and Pawlik, {Timothy M.} and Daniel, {Hubert D.} and Rajesh Kannangai and Offerhaus, {G. Johan A.} and Velculescu, {Victor E.} and Linfang Wang and Shibin Zhou and Bert Vogelstein and Hruban, {Ralph H.} and Nick Papadopoulos and Jianqiang Cai and Torbenson, {Michael S} and Kinzler, {Kenneth W.}",
note = "Funding Information: We thank N. Silliman, J. Ptak, L. Dobbyn, J. Schaeffer, M. Whalen, Z. Khan, J. Ma, Z. Wang and R. Mi for expert technical assistance. This work was supported by The Virginia and D.K. Ludwig Fund for Cancer Research and US National Institutes of Health grants CA43460, CA57345, CA62924, CA121113, DK078686, DK080736, DK081417, AACR Stand Up to Cancer Dream Team Translational Cancer Research Grant and National Science and Technology Major Project Grant 2008ZX10002-025.",
year = "2011",
month = sep,
doi = "10.1038/ng.903",
language = "English (US)",
volume = "43",
pages = "828--829",
journal = "Nature genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "9",
}